FDA approves Veltassa to treat hyperkalemia
October 26th 2015FDA approved patiromer (Veltassa, Relypsa) oral suspension for the treatment of hyperkalemia. Hyperkalemia is the condition when blood potassium levels are higher than normal in the kidneys, which can lead to abnormal heart rhythms or sometimes death.
Read More
Study: Members not following updated statin therapy guidelines
October 26th 2015Prime Therapeutics conducted a study to estimate how many commercial members have ASCVD, but are not being treated with high-intensity statin therapy, as recommended in the 2013 ACC/AHA cholesterol guidelines. View the results.
Read More
FDA approves orphan drug for bleeding disorder
October 21st 2015The FDA this week approved Coagadex, Coagulation Factor X (Human) for hereditary Factor X (10) deficiency. Until the new orphan drug approval, no specific coagulation factor replacement therapy was available for patients with hereditary Factor X deficiency.
Read More
[BLOG]: Diagnostics as aids for specialty drug treatment
October 21st 2015Laboratory diagnostics are essential tools of physician practice, informing many medical decisions. Physicians will increasingly rely on companion and other types of lab diagnostics that consider genetic, proteomic, or other markers in connection with drug treatment strategies.
Read More
[BLOG]: Pain management: Can we balance patient access, safety and economic value?
October 21st 2015Pain management is a problem for patients, practitioners, pharmacists, and others. Many patients are not getting the care and relief they deserve, even when they suffer from acute or chronic pain. In this blog post, Srinivas Nalamachu, MD asks if its possible to balance patient access to pain medication with safety and economic value.
Read More
Judge rules: Orphan drugs not subject to 340B discounts
October 16th 2015Judge Rudolph Contreras ruled against the Department of Health and Human Services by saying that pharma companies do not have to offer rural and cancer hospitals that serve low-income populations 340B discounts on orphan drugs.
Read More